LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 102 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is 2.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $47,295 | +3.4% | 31,530 | 0.0% | 0.01% | -18.2% |
| Q4 2022 | $45,719 | +8.9% | 31,530 | -14.8% | 0.01% | -8.3% |
| Q3 2022 | $42,000 | -46.8% | 37,008 | -25.6% | 0.01% | -40.0% |
| Q2 2022 | $79,000 | -17.7% | 49,736 | -20.4% | 0.02% | -13.0% |
| Q1 2022 | $96,000 | -39.6% | 62,488 | -4.0% | 0.02% | -43.9% |
| Q4 2021 | $159,000 | -11.2% | 65,069 | -7.9% | 0.04% | -22.6% |
| Q3 2021 | $179,000 | -2.2% | 70,625 | +10.0% | 0.05% | -18.5% |
| Q2 2021 | $183,000 | +20.4% | 64,232 | -0.6% | 0.06% | -11.0% |
| Q1 2021 | $152,000 | +28.8% | 64,614 | -3.4% | 0.07% | +5.8% |
| Q4 2020 | $118,000 | +81.5% | 66,917 | -4.2% | 0.07% | +40.8% |
| Q3 2020 | $65,000 | +25.0% | 69,874 | +17.2% | 0.05% | -3.9% |
| Q2 2020 | $52,000 | – | 59,597 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
| Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
| Raffles Associates | 93,590 | $236,000 | 0.22% |
| Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
| DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
| Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
| Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
| Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |